Pain Management

The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.

The over-the-counter (OTC), drug-free medical device, ActiPatch®, has obtained a new 510(k) clearance from the Food and Drug Administration (FDA) for the adjunctive treatment of musculoskeletal pain.

Twenty nine percent of prescribed opioids exceed recommended morphine equivalent for pain management.

Epidiolex is currently approved in the US to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Among 11 states, daily dosage declined the least in Idaho and Maine, the most in Florida.

Eli Lilly announced the launch of Reyvow (lasmiditan) for the acute treatment of migraine with or without aura in adult patients.

Twenty-nine point four percent of patients with 2 or more visits for new LBP received advanced imaging within the first year.

Top 1% of providers account for 49% of all opioid doses, 27% of all opioid prescriptions.

The FDA has approved an autoinjector device for Ajovy (fremanezumab-vfrm; Teva) injection for the preventive treatment of migraine in adults.

The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) was split (6 to 6) on its decision as to whether Posimir (bupivacaine extended-release solution; Durect) should be approved for post-surgical analgesia.